http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Gyung-Min,Kim, Seon Ha,Jo, Min-Woo,Her, Sung Ho,Han, Seungbong,Ahn, Jung-Min,Park, Duk-Woo,Kang, Soo-Jin,Lee, Seung-Whan,Kim, Young-Hak,Lee, Cheol Whan,Kim, Beom-Jun,Koh, Jung-Min,Kim, Hong-Kyu Williams & Wilkins Co 2015 Medicine Vol.94 No.21
<P><B>Abstract</B></P><P>It is not clear whether screening by coronary computed tomographic angiography (CCTA) and/or exercise electrocardiogram (ECG) can improve clinical outcomes and reduce costs in individuals without known cardiovascular disease (CVD).</P><P>In total, 71,811 consecutive individuals without known CVD who underwent general health examinations were enrolled. Using propensity-score matching according to screening tests, 1-year clinical outcomes and 6-month total and coronary artery disease–related medical costs were analyzed in separate groups: group 1 (CCTA [n = 2578] vs no screening [n = 5146]), group 2 (exercise ECG [n = 2898] vs no screening [n = 5796]), and group 3 (CCTA and exercise ECG [n = 2003] vs no screening [n = 4006]).</P><P>There were no significant differences in the composite outcome of death, myocardial infarction, and stroke in each matched group: group 1 (0.35% vs 0.45%, <I>P</I> = 0.501), group 2 (0.14% vs 0.28%, <I>P</I> = 0.157), and group 3 (0.25% vs 0.27%, <I>P</I> = 0.858). However, revascularization was more frequent in the CCTA screening groups: group 1 (2.02% vs 0.45%, <I>P</I> < 0.001) and group 3 (1.40% vs 0.45%, <I>P</I> < 0.001). Matched screening groups had higher 6-month total and coronary artery disease–related medical costs: group 1 ($777 vs $603, <I>P</I> < 0.001 and $177 vs $39, <I>P</I> < 0.001), group 2 ($544 vs $492, <I>P</I> = 0.045 and $12 vs $15, <I>P</I> = 0.611), and group 3 ($705 vs $627, <I>P</I> = 0.090 and $135 vs $35, <I>P</I> < 0.001).</P><P>In individuals without known CVD, CCTA screening with or without exercise ECG led to more frequent revascularization at the expense of higher medical costs, but did not decrease the 1-year risk of death, myocardial infarction, and stroke.</P>
Park, Gyung-Min,Kim, Young-Hak,Yun, Sung-Cheol,Ahn, Jung-Min,Choi, Hyo-In,Roh, Jae-Hyung,Lee, Pil Hyung,Chang, Mineok,Lee, Sang Gyu,Jo, Min-Woo,Park, Duk-Woo,Kang, Soo-Jin,Lee, Seung-Whan,Lee, Cheol W Society of Nuclear Medicine 2016 The Journal of nuclear medicine Vol.57 No.9
<P>Little data are available to compare the clinical implications of coronary angiography (CAG) or myocardial perfusion imaging (MPI) as an initial evaluation for stable coronary artery disease (CAD). Methods: From national health insurance claims data in South Korea, patients aged 18 y or older without a known history of CAD, who underwent CAG or MPI for the diagnosis of stable CAD between 2009 and 2013, were enrolled. Patients were divided into CAG (n = 117,134) and MPI (n = 19,932) groups. The primary endpoint, defined as a composite of all cause death and myocardial infarction, was compared by a propensity score analysis between the 2 groups. Results: There was a significant increase (39%) in the annual rate of CAG from 23,985 in 2009-2010 to 33,373 in 2012-2013. However, a substantial reduction (41%) in the annual MPI rate was also noted from 6,389 in 2009-2010 to 3,790 in 2012-2013. During the follow-up period (median, 2.4 y; interquartile range, 1.5-3.5), coronary revascularization was more frequently performed in the CAG group (adjusted hazard ratio [aHR] of CAG, 24.15; 95% confidence interval [CI], 19.66-29.68; P < 0.001). However, the incidence of the primary endpoint was significantly higher in the CAG group (aHR, 1.26; 95% CI, 1.17-1.36; P < 0.001). The individual end-points of death (aHR, 1.16; 95% CI, 1.06-1.25; P = 0.001) and myocardial infarction (aHR, 1.95; 95% CI, 1.60-2.36; P < 0.001) were also higher in the CAG group. Conclusion: As an initial diagnostic test in patients with stable CAD, MPI is associated with a better clinical outcomes than CAG.</P>
Impact of ad hoc percutaneous coronary intervention with drug-eluting stents in angina patients.
Kim, Young-Hak,Park, Duk-Woo,Ahn, Jung-Min,Park, Gyung-Min,Cho, Yong-Rak,Lee, Jong-Young,Kim, Won-Jang,Yun, Sung-Cheol,Kang, Soo-Jin,Lee, Seung-Whan,Lee, Cheol Whan,Park, Seong-Wook,Park, Seung-Jung Société Europa édition 2013 EuroIntervention Vol.9 No.1
<P>To evaluate the impact of ad hoc percutaneous coronary intervention (PCI) which combines coronary angioplasty and PCI in the same procedure in the era of drug-eluting stents (DES).</P>
Park, Gyung-Min,Yun, Sung-Cheol,Cho, Young-Rak,Gil, Eun Ha,Her, Sung Ho,Kim, Seon Ha,Jo, Min-Woo,Lee, Moo Song,Lee, Seung-Whan,Kim, Young-Hak,Yang, Dong Hyun,Kang, Joon-Won,Lim, Tae-Hwan,Kim, Beom-Jun Kluwer Academic Publishers 2015 INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING Vol.31 No.3
<P>We sought to estimate the prevalence of coronary atherosclerosis by coronary computed tomographic angiography (CCTA) and to identify risk factors attributable to the development of coronary atherosclerosis in an asymptomatic Asian population. We analyzed 6,311 consecutive asymptomatic individuals aged 40 and older with no prior history of coronary artery disease (CAD) who voluntarily underwent CCTA evaluation as part of a general health examination. The mean age of study participants was 54.7 7.4 years, and 4,594 (72.8%) were male. After age and gender adjustment using the population census of the National Statistical Office, the prevalence of plaque was 40.5% [95% confidence interval (CI) 38.1-42.9], and significant CAD (diameter stenosis 50%) was observed in 9.0% (95% CI 7.7-10.2). Individuals with significant CAD were significantly older than those without (59.2 8.8 vs. 54.0 7.1 years, p < 0.001). Compared with individuals with no cardiovascular risk factors, there was a higher prevalence of significant CAD in individuals with diabetes mellitus [standardized rate ratio (SRR) 2.66; 95% CI 1.93-3.68; p < 0.001], hypertension (SRR 2.24; 95% CI 1.69-2.97; p < 0.001), or hyperlipidemia (SRR 1.65; 95% CI 1.25-2.17; p < 0.001). There was also a greater prevalence of significant CAD in individuals with an intermediate or high Framingham risk score (SRR 5.91; 95% CI 2.34-14.95; p < 0.001) or a high atherosclerotic cardiovascular disease risk score (SRR 8.04; 95% CI 3.04-21.23; p < 0.001). The prevalence of coronary atherosclerosis in this Asian population was not negligible and was associated with known cardiovascular risk factors and high-risk individuals.</P>
Won-Bin Lee,Seong-Been Kim,Kyoung-Whan Kim,Kyung-Jin Lee,Hyun-Cheol Koo,Gyung-Min Choi 한국자기학회 2021 한국자기학회 학술연구발표회 논문개요집 Vol.31 No.2
For semiconductor spintronics, efficient spin generation in semiconductor and spin transfer to ferromagnetic metal (FM) are essentially required. Two-dimensional electron gas (2DEG) of semiconductor quantum wells is a promising system for generating spin via Rashba–Edelstein effect (REE) because of its strong inversion symmetry breaking. In this study, we investigate spin accumulation through REE and spin Hall effect (SHE) in the 2DEG of an InAs quantum well. We use spatial- and vector-resolved measurements of spin, which reveals that REE dominates SHE in 2DEG. Furthermore, REE in 2DEG induces a spin-orbit torque on FM in a 2DEG/insulator/FM heterostructure. Using vector- and time-resolved measurements of FM magnetization, we determine a sizeable field-like torque, which is attributed to the phonon-mediated spin transport from 2DEG to FM. 〈그림 본문참조〉
Won-Bin Lee,Seong-Been Kim,Kyung-Jin Lee,Kyoung-Whan Kim,Hyun-Cheol Koo,Gyung-Min Choi 한국자기학회 2021 한국자기학회 학술연구발표회 논문개요집 Vol.31 No.1
The momentum and spin of electrons are coupled by spin-orbit interaction and this coupling plays an important role in spintronics. The Rashba and spin Hall effects are two of the most representative phenomena due to the spin-orbit coupling (SOC) and conversion between charge and spin is possible by applying these effects. In this research, we investigated the spin-orbit coupling in InAs based two-dimensional electron gas (2DEG) quantum well structure directly by using the magneto-optical method. We applied a charge current into the InAs 2DEG sample, and directly observed current-induced spin accumulation in InAs 2DEG due to the spin-orbit coupling (SOC) by using the magneto-optic Kerr effect (MOKE). As a result, both in-plane spin accumulation throughout the channel by Rashba-Edelstein effect and out-of-plane spin accumulation by spin Hall effect at the edges of the channel were confirmed.
Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II
Choi, Min Hee,Lee, In Kyung,Kim, Gyung Whan,Kim, Bang Ul,Han, Ying-Hao,Yu, Dae-Yeul,Park, Hye Sun,Kim, Kyung Yong,Lee, Jong Seo,Choi, Chulhee,Bae, Yun Soo,Lee, Byung In,Rhee, Sue Goo,Kang, Sang Won Nature Publishing Group 2005 Nature Vol.435 No.7040
Platelet-derived growth factor (PDGF) is a potent mitogenic and migratory factor that regulates the tyrosine phosphorylation of a variety of signalling proteins via intracellular production of H<SUB>2</SUB>O<SUB>2</SUB> (refs 1, 2–3). Mammalian 2-Cys peroxiredoxin type II (Prx II; gene symbol Prdx2) is a cellular peroxidase that eliminates endogenous H<SUB>2</SUB>O<SUB>2</SUB> produced in response to growth factors such as PDGF and epidermal growth factor; however, its involvement in growth factor signalling is largely unknown. Here we show that Prx II is a negative regulator of PDGF signalling. Prx II deficiency results in increased production of H<SUB>2</SUB>O<SUB>2</SUB>, enhanced activation of PDGF receptor (PDGFR) and phospholipase Cγ1, and subsequently increased cell proliferation and migration in response to PDGF. These responses are suppressed by expression of wild-type Prx II, but not an inactive mutant. Notably, Prx II is recruited to PDGFR upon PDGF stimulation, and suppresses protein tyrosine phosphatase inactivation. Prx II also leads to the suppression of PDGFR activation in primary culture and a murine restenosis model, including PDGF-dependent neointimal thickening of vascular smooth muscle cells. These results demonstrate a localized role for endogenous H<SUB>2</SUB>O<SUB>2</SUB> in PDGF signalling, and indicate a biological function of Prx II in cardiovascular disease.